{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:39:47Z","timestamp":1777649987057,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.msard.2022.103960","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T16:45:54Z","timestamp":1654879554000},"page":"103960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?"],"prefix":"10.1016","volume":"65","author":[{"given":"Sepideh","family":"Paybast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Emami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Baghalha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-0911","authenticated-orcid":false,"given":"Abdorreza","family":"Naser Moghadasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103960_bib0024","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.wneu.2020.05.193","article-title":"COVID-19 and SARS-Cov-2 infection: pathophysiology and clinical effects on the nervous system","volume":"140","author":"Abboud","year":"2020","journal-title":"World Neurosurg."},{"issue":"2","key":"10.1016\/j.msard.2022.103960_bib0034","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.103960_bib0035","article-title":"Current and emerging therapeutics for neuromyelitis optica spectrum disorder: relevance to the COVID-19 pandemic","volume":"44","author":"Abboud","year":"2020","journal-title":"Multiple Sclerosis Relat. Disord."},{"key":"10.1016\/j.msard.2022.103960_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577236","article-title":"Risk factors of attacks in neuromyelitis optica spectrum disorders","volume":"343","author":"Akaishi","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2022.103960_bib0014","article-title":"Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: case report and systematic review","author":"Anamnart","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2022.103960_bib0015","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1016\/j.radcr.2021.09.033","article-title":"Post COVID-19 vaccination neuromyelitis optica spectrum disorder: case report & MRI findings","volume":"16","author":"Badrawi","year":"2021","journal-title":"Radiol. Case Rep."},{"issue":"2","key":"10.1016\/j.msard.2022.103960_bib0031","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2022.103960_bib0032","article-title":"Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?","author":"Baker","year":"2021","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2022.103960_bib0008","article-title":"Rituximab for the treatment of neuromyelitis optica spectrum disorder","volume":"1","author":"Banerjee","year":"2021","journal-title":"Can. J. Health Technol."},{"key":"10.1016\/j.msard.2022.103960_bib0010","article-title":"COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis","author":"Barzegar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103960_bib0012","doi-asserted-by":"crossref","DOI":"10.1097\/NRL.0000000000000420","article-title":"A case with new-onset neuromyelitis optica spectrum disorder following COVID-19 mRNA BNT162b2 vaccination","author":"Caliskan","year":"2022","journal-title":"Neurologist"},{"issue":"11","key":"10.1016\/j.msard.2022.103960_bib0039","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1007\/s00415-021-10545-2","article-title":"Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus","volume":"268","author":"Centonze","year":"2021","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2022.103960_bib0016","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1007\/s10072-021-05427-4","article-title":"Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19","volume":"42","author":"Chen","year":"2021","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2022.103960_bib0001","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1017\/cjn.2020.146","article-title":"Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis","volume":"48","author":"Collantes","year":"2021","journal-title":"Can. J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2022.103960_bib0036","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.vaccine.2017.01.048","volume":"35","author":"Croce","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2022.103960_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103424","article-title":"Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD","volume":"58","author":"Dinoto","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103960_bib0038","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3389\/fimmu.2021.656362","article-title":"How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: an expert opinion by IMIDs study group","volume":"12","author":"Ferretti","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2022.103960_bib0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/jalm\/jfab150","article-title":"Pathobiology, diagnosis, and current biomarkers in neuromyelitis optica spectrum disorders","volume":"7","author":"Fiala","year":"2022","journal-title":"J. Appl. Lab. Med."},{"issue":"3","key":"10.1016\/j.msard.2022.103960_bib0007","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/CON.0000000000000742","article-title":"Neuromyelitis optica spectrum disorder and other non\u2013multiple sclerosis central nervous system inflammatory diseases","volume":"25","author":"Flanagan","year":"2019","journal-title":"Continuum"},{"key":"10.1016\/j.msard.2022.103960_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103321","article-title":"New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19","volume":"57","author":"Fragoso","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2022.103960_bib0013","article-title":"Neuromyelitis optica in a healthy female after severe acute respiratory syndrome coronavirus 2 mRNA-1273 vaccine","volume":"13","author":"Fujikawa","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.msard.2022.103960_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577439","article-title":"A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection","volume":"350","author":"Ghosh","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2022.103960_bib0026","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/vaccines10020279","article-title":"Multiple sclerosis patients and disease modifying therapies: impact on immune responses against COVID-19 and SARS-CoV-2 vaccination","volume":"10","author":"Golshani","year":"2022","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.msard.2022.103960_bib0002","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ana.26065","article-title":"ANA investigates neurological complications of COVID-19 vaccines","volume":"89","author":"Goss","year":"2021","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103960_bib0003","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40257-015-0124-x","article-title":"Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists","volume":"16","author":"Goyal","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.msard.2022.103960_bib0019","article-title":"Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica","author":"Januel","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.103960_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103320","article-title":"COVID-19 and vaccination against SARS-CoV-2 in patients with Neuromyelitis optica spectrum disorders","volume":"57","author":"Jovicevic","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2022.103960_bib0022","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103960_bib0011","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00277-021-04662-1","article-title":"Impact of rituximab on COVID-19 outcomes","volume":"100","author":"Levavi","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.msard.2022.103960_bib0005","first-page":"14","article-title":"Clinical features and imaging findings of myelin oligodendrocyte glycoprotein-IgG-associated disorder (MOGAD)","author":"Li","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.msard.2022.103960_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103189","article-title":"Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases","volume":"55","author":"Lotan","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103960_bib0027","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.05.003","article-title":"Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Mealy","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.103960_bib0028","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1212\/WNL.0b013e31825fdead","article-title":"Neuromyelitis optica following human papillomavirus vaccination","volume":"79","author":"Menge","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103960_bib0030","unstructured":"Organization WH. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. 2018."},{"issue":"1","key":"10.1016\/j.msard.2022.103960_bib0037","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1203475418811335","article-title":"Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies","volume":"23","author":"Papp","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.msard.2022.103960_bib0009","article-title":"Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis","author":"Schiavetti","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.103960_bib0033","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40120-021-00288-7","article-title":"Multiple sclerosis, COVID-19 and vaccines: making the point","volume":"10","author":"Toscano","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2022.103960_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102869","article-title":"Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature","volume":"50","author":"Velasco","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103960_bib0025","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3389\/fimmu.2019.01883","article-title":"Vaccination in multiple sclerosis: friend or foe?","author":"Zrzavy","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822004710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822004710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:31Z","timestamp":1761901351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822004710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"alternative-id":["S2211034822004710"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103960","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103960"}}